Health Care [ 9/12 ] | Health Care Equipment & Supplies [ 43/73 ]
NASDAQ | Common Stock
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications.
The company offers aurora and northern lights systems delivers cell analysis; aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; enhanced small particle detection; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.
It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments.
In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools.
It serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations.
The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries.
The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015.
Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 5, 25 | -0.03 Increased by +45.60% | -0.04 Increased by +32.00% |
| Feb 28, 25 | 0.12 Increased by +188.75% | 0.10 Increased by +11.81% |
| Nov 6, 24 | 0.06 Increased by +211.60% | 0.04 Increased by +52.04% |
| Aug 6, 24 | -0.08 Decreased by -166.67% | -0.03 Decreased by -166.67% |
| May 8, 24 | -0.05 Increased by 0.00% | -0.04 Decreased by -25.00% |
| Feb 28, 24 | 0.04 Decreased by -33.33% | 0.01 Increased by +300.00% |
| Nov 7, 23 | -0.05 Decreased by -225.00% | 0.03 Decreased by -266.67% |
| Aug 8, 23 | -0.03 Decreased by -200.00% | 0.03 Decreased by -200.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 41.46 M Decreased by -7.59% | -11.40 M Decreased by -84.83% | Decreased by -27.50% Decreased by -100.00% |
| Dec 31, 24 | 57.48 M Decreased by -1.30% | 9.64 M Increased by +75.23% | Increased by +16.78% Increased by +77.54% |
| Sep 30, 24 | 51.50 M Increased by +7.29% | 941.00 K Increased by +114.58% | Increased by +1.83% Increased by +113.59% |
| Jun 30, 24 | 46.62 M Decreased by -6.19% | -10.43 M Decreased by -137.78% | Decreased by -22.38% Decreased by -153.47% |
| Mar 31, 24 | 44.86 M Increased by +20.96% | -6.17 M Increased by +9.37% | Decreased by -13.75% Increased by +25.07% |
| Dec 31, 23 | 58.23 M Increased by +20.48% | 5.50 M Increased by +55.94% | Increased by +9.45% Increased by +29.43% |
| Sep 30, 23 | 48.00 M Increased by +18.59% | -6.46 M Decreased by -487.52% | Decreased by -13.45% Decreased by -426.78% |
| Jun 30, 23 | 49.69 M Increased by +23.74% | -4.39 M Decreased by -633.78% | Decreased by -8.83% Decreased by -493.00% |